Ranbaxy restarts generic Lipitor productionReports stated that the company had recalledAtorvastatin for select batches in the strengthsof 10 mg, 20 mg and 40 mg tablets from the USmarket due to presence of foreign particles.
Conti... Ranbaxy reported a consolidated net loss of Rs 492 crore for the fourth quarter ended December 31, mainly due to its voluntary recall of Atorvastatin calcium tablets from the US.
Pharmexcil projects Rs 75,000 cr mark for Pharma exportsPharma exports from Indian players for 2012-13 mighttouch the Rs 75,000 crore mark. This shall account fora hike by 25 per cent from last year.The pharma export level stood at Rs 17,000 crore for2004. This is sharp contrast against the 2012 figuresof Rs 63,000 crore.The countries that see maximum exports from Indiaare USA( 27%), Europe (19%), Africa (17%), theMiddle East (7%), Latin America( 6%) and theCommonwealth of Independent States (CIS)Countries(5%).
Conti....In 2010, the Commerce Ministry announced pharma exporttarget at USD 25 billion by the year 2014. However, Appaji PV,Director General of Pharmexcil said that to be pragmatic, thetarget year could extend to 2016 in light of the global economicscenario.Pharmexcil endeavors to set up a warehouse in Nigeria with aidfrom the Commerce Ministry, in a move to support tradingcommunities. This is a first of its kind of measure. Theorganization was present at Chennai for announcing "iPHEX2013"- a three-day pharma road show scheduled to start on 24April in Mumbai. 250 companies would be part of the show.
DIPP looks for details on 3 cancer drugs for compulsory licensingDepartment of Industrial Policy and Promotion (DIPP)has sought details from the Health Ministry regardingthree medicines sold by multi-nationals Roche andBristol-Myers Squibb in India to make them affordable.Earlier in last month, the Health Ministry had approachedthe DIPP for issuance of compulsory licences (CLs) forthree anti-cancer drugs — Trastuzumab, Ixabepiloneand Dasatinib — which are very expensive.One vial (of 50 ml) of 40 mg trastuzumab costs Rs.1.24lakh, 60 tablets of 20mg each of dasatinib priced atRs.1.17 lakh. Similarly, one vial of 45 mg of ixabepilonecosts Rs.66,430.
Conti...Under the Indian Patents Act, a CL can be issued for adrug if the medicine is deemed unaffordable by thegovernment and grants permission to qualified genericdrug makers to manufacture it.As per the WTO agreement, a CL can be invoked by anational government allowing a company to produce apatented product without the consent of the patent ownerin public interest.
Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plcBristol-Myers Squibb Company announced thatit has entered into a three-year collaborationagreement with Reckitt Benckiser Group plc forits over-the-counter medicines currently soldacross Latin America, primarily in Mexico andBrazil.Under the terms of the collaboration agreement,Reckitt Benckiser will pay Bristol-Myers Squibban upfront payment in the amount of $438million for the exclusive rights to sell, distributeand market the following medicines for a three-year period:
Conti... Picot, an antacid, Tempra, a pain reliever and fever reducer, Micostatin, an antifungal, and Graneodin, a cough and cold medicine, sold primarily in Mexico; and Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and Naldecon, a cold and flu symptoms treatment, sold primarily in Brazil.
Conti... During the collaboration term, Bristol-Myers Squibb will retain responsibility for manufacturing all of the products covered by the collaboration (either by itself or through third party manufacturers), and Reckitt Benckiser will purchase products from Bristol-Myers Squibb and pay royalties on product sales during the term of the collaboration.
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with1)The Lusaka University Teaching Hospital (UTH),2)The Ministry of Health in Zambia,3)The Pan-African Cardiology Society and Massachusetts General Hospital (MGH).
Conti... RHD is a complication of untreated streptococcal infections in which the valves of the heart are scarred and eventually degenerate, leading to heart failure. Eliminated by antibiotic treatment in most developed nations, in the developing world an estimated 15 million children suffer from this debilitating and often fatal disease.
Said by Mark C. Fishman, Cardiologist and President of the Novartis Institutes for BioMedical Research (NIBR). The toll of heart failure in young children with RHD in Zambia is immense, for the patient, their families, and the nation. For the past several years Novartis has been working with colleagues in Lusaka to help, understand and treat asthma in young children. Novartis is expanding the collaboration to raise awareness, educate, and provide antibiotic therapy to prevent RHD."
Conti..Novartis will use portableechocardiography machines to evaluate3,000 children, ages 9-10, in Lusaka-areapublic schools.
Venus sign exclusive marketingrights deal for Antibiotic Ajuvant entityVenus Remedies Limited, the research basedglobal pharmaceutical company has accordexclusive marketing rights for its novel antibioticproduct – POTENTOX to South Africa’spharmaceutical giant Adcock in a deal companyannounced.POTENTOX is a research based antibioticproduct of the company protected by patent inUSA and in number of other countries across theGlobe including India, Canada, Australia, NewZealand, South Korea, South Africa andUkraine.
Conti... Adcock will have exclusive marketing rights of the product in South Africa over the period of 15 year. The product will remain under patent protection till 2025 in African territory and is expected to be launched by mid of 2015 after getting due regulatory approvals.
Biocon is eyeing Rs 100 cr in sales in thenext four years from psoriasis drug that itplans to launch under the brand Alzumabin the country in the current year.
Glenmark Pharma gets USFDA nod for HIV drug Glenmark Pharmaceuticals said that the US Food and Drug Administration has provided marketing approval to its partner in the US, Salix Pharmaceuticals Limited, for Crofelemer, which provides relief to patients with diarrhea HIV and AIDS on anti-retroviral therapy.
US FDA approves Stivarga for advanced GISTGastrointestinal stromal tumours (GIST) is atumour in which cancerous cells form in thetissues of the gastrointestinal tract, part of thebody’s digestive systemThe US Food and Drug Administration (US FDA)expanded the approved use of Stivarga(Regorafenib) to treat patients with advancedgastrointestinal stromal tumours (GIST) thatcannot be surgically removed and no longerrespond to other FDA-approved treatments for
Conti... Stivarga is the third drug approved by the FDA to treat gastrointestinal stromal tumours. Stivarga was approved in September 2012 to treat colorectal cancer. It is marketed by Bayer HealthCare Pharmaceuticals, based in Wayne, NJ. Gleevec is marketed by East Hanover, NJ- based Novartis, and Sutent is marketed by New York City-based Pfizer.